Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
May, 2026
May 2026
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031
Michael Makris: The 4-Year Results From the Hemgenix Study in Patients Without Neutralising Antibodies Published in RPTH Journal
Michael Makris/LinkedIn
Jan 6, 2026, 07:21

Michael Makris: The 4-Year Results From the Hemgenix Study in Patients Without Neutralising Antibodies Published in RPTH Journal

Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, shared on LinkedIn:

“The natural history of gene therapy for hemophilia B is very different from that in hemophilia A. Following FIX gene therapy with Hemgenix, the FIX levels remain stable.
The 4-year results from the Hemgenix study in patients without neutralising antibodies have just been published in the journal Research and Practice in Thrombosis and Haemostasis.
The mean factor IX level after 4 years was 39%.
The PDF of the paper is freely available here.”

Title: Etranacogene dezaparvovec in participants with hemophilia B and without adenoassociated virus serotype 5 neutralizing antibodies: A 4-year subgroup analysis (HOPE-B)

Authors: Priyanka Raheja, Niamh O’Connell, Peter Verhamme, Peter Kampmann, Richard S. Lemons, Fei Wang, Sean Gill, Paul E. Monahan, Sandra Le Quellec, Frank W.G. Leebeek

Michael Makris: The 4-Year Results From the Hemgenix Study in Patients Without Neutralising Antibodies Published in RPTH Journal

More posts featuring Michael Makris on Hemostasis Today.

Factor IX Fei Wang FIX gene therapy Frank W. G. Leebeek Health Hemgenix Hemophilia B Hemostasis Hemostasis News Hemostasis Today Medicine Michael Makris Niamh O’Connell Paul E. Monahan Peter Kampmann Peter Verhamme Priyanka Raheja Richard S. Lemons Sandra Le Quellec Sean Gill thrombosis
NewsFeed